Interview with Dr Samer Al Hadidi, Editor
University of Arkansas for Medical Sciences, AR, USA
Set the Scene
Purpose: Prepare HCPs for the upcoming scientific event, highlighting relevant sessions and emerging topics. Featuring:
•
Program editor video introducing key themes (2–4 min)
•
Written preview article outlining priority sessions and areas of interest (300–500 words)
•
Programme registration CTA to encourage HCP sign-up
Interview with Dr Samer Al Hadidi,
University of Arkansas for Medical Sciences, AR, USA
Written topics preview (bullet-points or infographic)
Creating Momentum
Purpose: Provide insights during the conference and highlight early implications for clinical practice. Featuring:
•
Short expert video interviews (3–5 min) recorded daily (remote or onsite) summarising top takeaways and potential practice impact
Day 1
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Day 2
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Day 3
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Day 4
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Reflect & Implement
Purpose: Consolidate learning and support practical integration into clinical care. Featuring:
•
Six concise written session summaries (300–500 words each) with downloadable slides or the Rise demo feature
•
Where relevant, Infographics visualising key findings
•
Short expert video reflections (4–6 min) aligned with session summaries
•
Science in Practice podcast series (3 × ~10 min episodes)
•
Educational & Practical tools: self-assessments, recommended further reading, patient perspective
Extended Podcast Series
Additional Expert Interviews
Interviews with principle investigators of major trials
Interview with Dr Francesco Maura,
Sylvester Comprehensive Cancer Center, University of Miami, FL, USA
Lisocabtagene Maraleucel
Lisocabtgene maraleucel, a CD19 directed CAR T-cell therapy, versus standard of care in the TRANSFORM trial
Interview with Dr Manali Kamdar,
University of Colorado Cancer Center, CO, USA
ZUMA-7, BELINDA and TRANSFORM Trials
Expert Opinion of ZUMA-7, BELINDA, and TRANSFORM randomised controlled trials
Interview with Prof. Martin Dreyling,
University of Munich, Germany
1981
Company fouded
200+
Conferences covered
120+
Countries reached
150,000
Physicians served
This is a demo website for presentation purposes only!
The views and opinions of the interviewees and presenters are their own, and do not necessarily represent the stance or responsibility of the Editor nor the Publisher. The content is provided for informational purposes only and should not be considered official editorial content, endorsement or medical advice.
Copyright 2026: Medicom Education
BV